Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

Presentation raises questions about EBV timing. Dalia Rotstein, MD, of the University of Toronto, discussed the findings and their implications in an oral presentation at the Amer ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological conditions, according to a new study that analyzed cryopreserved CSF samples ...

Learn how early diagnosis and modern therapies can prevent Multiple Sclerosis from leading to long-term disability.

Specialists in multiple sclerosis will gather in San Diego for ACTRIMS Forum 2026, Feb. 5-7, where the theme will be “MS at a ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

Intermountain Ventures is collaborating with a health tech startup to earlier identify cases of multiple sclerosis. The venture capital and innovation arm of Salt Lake City-based Intermountain Health ...

MS pain is the uninvited guest you can't turn away, columnist Desiree Lama writes. Listening to your body is the key to ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.